Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Excretion of Eragidomide in Healthy Men
NCT04297124Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eragidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Primary endpoints: Total [14C]- radioactivity (RA), Cumulative excretion of total [14C]-RA and 5 more. Started Mar 2020; status: completed.
02
Drugs
eragidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04297124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297124.